2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

Similar documents
as a Mechanism of Stent Failure

Insights in Thrombosis and In-Stent Restenosis

Can IVUS Define Plaque Features that Impact Patient Care?

Left main coronary artery (LMCA): The proximal segment

Imaging Atheroma The quest for the Vulnerable Plaque

OCT Findings: Lesson from Stable vs Unstable Plaques

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea

Catch-up Phenomenon: Insights from Pathology

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection

Pathology of Vulnerable Plaque Angioplasty Summit 2005 TCT Asia Pacific, Seoul, April 28-30, 2005

Optical Coherence Tomography for Intracoronary Imaging

Added Value of Invasive Coronary Imaging for Plaque Rupture and Erosion

Assessment of Vulnerable Plaque by IVUS and VH-IVUS

Appearance of Lipid-Laden Intima and Neovascularization After Implantation of Bare-Metal Stents

Drug eluting stents (DES) have decreased

Plaque Characteristics in Coronary Artery Disease. Chourmouzios Arampatzis MD, PhD, FESC

Pathology of Coronary Artery Disease

High-risk vulnerable plaques. Kostis Raisakis G.Gennimatas General Hospital of Athens

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent

Vulnerable Plaque Pathophysiology, Detection, and Intervention. VP: A Local Problem or Systemic Disease. Erling Falk, Denmark

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

Cardiovascular Research Foundation and Columbia University Medical Center, New York.

OCT Analysis in Patients With Very Late Stent Thrombosis

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Invasive Imaging (IVUS, VH-IVUS, and OCT): How I Implement into My

Coronary Artery Thermography

Characteristics of Neoatherosclerosis Within Implanted Coronary Stents in Patients with Acute Coronary Syndromes

Prognostic Value of Gated Myocardial Perfusion SPECT

What Does the Yellow Color of Angioscopy Mean? Why Yellow Plaque Is Always Vulnerable?

Que nos puede aportar el OCT intracoronario

Can We Identify Vulnerable Patients & Vulnerable Plaque?

Assessment of plaque morphology by OCT in patients with ACS

Biology of in-stent restenosis and rational for debulking

Histopathology: Vascular pathology

Review Article Optical Coherence Tomography Imaging in Acute Coronary Syndromes

Chapter 43 Noninvasive Coronary Plaque Imaging

Multimodality Imaging Atlas of Coronary Atherosclerosis

Optical Coherence Tomography

Sites of Atherosclerosis In order of Frequency

1st Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece

Pathophysiology of Cardiovascular System. Dr. Hemn Hassan Othman, PhD

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

Pathology of the Vulnerable Plaque

Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation

Evaluation of stent placement and outcomes with optical coherence tomography

SMJ Singapore Medical Journal

Gary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function

Muzina Akhtar, Wei Liu. History of ISR visualization. Introduction

Fielder XT: Initial and. Department of Cardiology, Asan Medical Center, Ulsan University of college of medicine

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Davide Capodanno, MD, PhD Associate Professor, University of Catania, Italy

Assessment of Coronary Plaque Vulnerability with Optical Coherence Tomography

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

The Pathology of Neoatherosclerosis in Human Coronary Implants

BIOFREEDOM: Polymer free Biolimus A9 eluting

Clinical Application of OCT in Stent Evaluation

Tratamiento de la Reestenosis del Stent Farmacoactivo

Assessment of vulnerable plaque by OCT

CPIS So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of MedicineSuwon, Korea

Advance Publication. Atherosclerotic Component of the Yellow Segment After Drug-Eluting Stent Implantation on Coronary Angioscopy

TVA_C02.qxd 8/8/06 10:27 AM Page 19 PART 2. Pathology

Failure of positive. Recanalization and CTO formation. TCFA rupture with (fatal) thrombotic occlusion. TCFA Lipid pool

Clinical Characteristics of In-stent Neoatherosclerosis Causing Late Stent Failure

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

Usefulness of OCT during coronary intervention

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans

Bifurcation Stenting: IVUS and OCT Information

Cover Page. The handle holds various files of this Leiden University dissertation.

RESTENOSIS Facing up to the problem

Optical Coherence Tomography (OCT): A New Imaging Tool During Carotid Artery Stenting

Research Article Pathological Perspective of Drug-Eluting Stent Thrombosis

malapposition assessed by OCT

Stent Fracture and Longitudinal Compression on CT Angiography between the

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

Plaque Imaging: What It Can Tell Us. Kenneth Snyder, MD, PhD L Nelson Hopkins MD FACS Elad Levy MD MBA FAHA FACS Adnan Siddiqui MD PhD

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.

Drug Eluting Stent DES Pathology Update What we know, what we do not know

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

State of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC

OCT GUIDED TREATMENT OF CALCIFIED LESIONS RICHARD SHLOFMITZ, MD CHAIRMAN OF DEPT. OF CARDIOLOGY ST. FRANCIS HOSPITAL ROSLYN, NEW YORK

Citation Journal of Cardiology Cases (2013), Ltd.; この論文は出版社版でありません 引用の際には出版社版をご確認ご利用ください This is not the publ

Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis

IVUS vs FFR Debate: IVUS-Guided PCI

Index. B Bare metal stents (BMS) vs. DES, 172 OCT findings, 170, 172

Between Coronary Angiography and Fractional Flow Reserve

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

DES In-stent Restenosis

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Ambiguity in Detection of Necrosis in IVUS Plaque Characterization Algorithms and SDH as Alternative Solution

In-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»

In-Stent Restenosis. Can we kill it?

Transcription:

Pathology of In-stent Neoatherosclerosis in BMS and DES 197 BMS, 103 SES, and 106 PES with implant duration >30 days The incidence of neoatherosclerosis was significantly greater in DES (31%) than BMS (16%; p < 0.001). Median stent duration with neoatherosclerosis was shorter in DES than BMS (420 days v 2,160 days, p < 0.001). 2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% 7 BMS and 3 DES had TCFA or plaque rupture occurring with shorter implant durations for DES (1.5±0.4 years) compared to BMS (6.1±1.51.5 years). Nakazawa et al. J Am Coll Cardiol 2011;57:1314-22

Percentage of Patients With Atherosclerotic Changes in DES Versus BMS in Relation to Duration of Implant at Autopsy Nakazawa et al. J Am Coll Cardiol Img 2009;2:625-8

In-stent Morphologies and OFDI Appearance Histology Collagen-rich neointima Proteoglycan-rich neointima Fibrin deposition OFDI description bright and homogenous tissue, smooth luminal surface relatively dark tissues, smooth luminal surface relatively light around luminal area following by attenuation, heterogenous tissues with irregular surface Signal Analysis Intensity Attenuation Strong Gentle Medium Gentle Medium Moderate Lipid core dark area without clear borders, more cholesterol crystal content likely to be darker* Weak Steep Foamy Macrophage accumulation Organized thrombus thin bright layer and following shadow Very Strong Steep dark area independent of surrounding tissues Weak Angiogenesis One or numerous black holes NA NA Calcified neointima a dark mass delineated with clear borders Weak Gentle Sudden Virmani et al. J Am Coll Cardiol Img 2009;2:625-8

Disruption of neointima In-stent calcification Neoangiogenesis

Organized thrombus Ca++ Ca++

TCFA in neointima

Macrophage infiltration on luminal surface 1 2 3 1 2 3 1 2 3

OCT and In-stent Neoatherosclerosis after BMS - I <6months >5years # 20 21 Lipid laden intimal 0 67% Intimal disruption 0 38% Thrombus 5% 52% Intraintimal neovasacularization 0% 62% Takano et al. J Am Coll Cardiol 2009;55:26-33 In 39 pts (60 BMS) who underwent OCT imaging 6.5±1.3ys after BMS implantation, lipid-rich neointima was found in 20 stents (33.3%) in 16 pts (41%) with an average fibrous cap thickness of 56.7±5.8µ. Six pts had plaque disruption and 6 patients had mural thrombus. Hou et al. Heart. 2010;96:1187-90.

OCT and In-stent Neoatherosclerosis after BMS - II >5 years <1 year P-value # 43 39 Homogeneous neointima* 39.5±28.5% 94.2±11.5% <0.0001 Heterogeneous neointima* 60.5%±28.5% 5.8±11.5% <0.0001 Microvessels* Peri-stent 25.6±18.6% 6.8±8.6% <0.0001 Neointima 13.1±12.8% 0 <0.0001 Disrupted neointima 18.6% 0 0.006 Intraluminal material 20.9% 2.6% 0.02 With shadowing 16.2% 0 0.01 Without shadowing 4.7% 2.6% 1.0 *of sections throughout the stent Habara et al. Circ Cardiovasc Interv 2011;4:232-8

Normal Intima and Atherosclerotic Intima Thrombus, Intimal Disruption, and Neovascularization Takano et al. J Am Coll Cardiol 2010;55:26-32

In-stent Neoatherosclerosis after DES (n=50, median follow-up of 32 months) 52% lesions had at least one in-stent TCFA-like neointima 58% had at least one in-stent neointimal rupture. Patients presenting with unstable angina showed Thinner fibrous cap (55µ vs. 100µ, p=0.006) Higher incidence of TCFA-like neointima (75% vs. 37%, p=0.008) Higher incidence of neointimal rupture (75% vs. 47%, p=0.044) Higher incidence of thrombi (80% vs. 43%, p=0.010) and red thrombi (30% vs. 3%, p=0.012) Kang et al. Circulation 2011;123:2954-2963

(composite of TCFA-like neointima, neointimal rupture, and red thrombus)

Late in-stent neoatherosclerosis in DES Microvessel TCFA-like neointima Calcium Neointimal rupture

Red thrombus White thrombus

VH Composition of Neointima at Various Follow-Up Times in 117 ISR Lesions Combining 47 BMS and 70 DES >36Mo (n=26) 52.2* 5.6* 27.2* 15.0* 24-36Mo (n=15) 54.9* 7.1 # 25.8* 12.2* 12-24Mo (n=12) 62.5 8.1 22.3 7.3 # 6-12Mo (n=42) 64.5 12.5 18.5 4.5 <6Mo (n=22) 67.2 15.4 14.6 2.8 0 20 40 60 80 100 (%) *p<0.01 and # p<0.05, vs. lesions at follow-up time <6 months Kang et al. Am J Cardiol. 2010;106:1561-5

VH Composition of Neointima at Various Follow-Up Times in 70 DES Restenosis Lesions >36Mo (n=0) 24-36Mo (n=10) 53.3* 6.2 # 26.4* 13.1* 12-24Mo (n=11) 63.5 7.7 21.3 7.5 # 6-12Mo (n=33) 65.2 12.3 18.0 4.5 <6Mo (n=16) 68.8 12.8 15.3 3.1 0 20 40 60 80 100 (%) *p<0.01 and #p<0.05, vs. lesions at follow-up time <6 months

Various Neointimal VH Composition at the Maximal %IH Sites 6-mo Taxus %NC 8% %DC 2% 9-mo Taxus %NC 28% %DC 8% 22-mo Taxus %NC 39% %DC 20% 48-mo BMS %NC 40% %DC 25% 57-mo BMS %NC 57% %DC 15%

VH-IVUS comparison of neointimal hyperplasia within 23 DES vs 15 BMS Follow-up was similar between DES (38 mos) vs. BMS (40 mos). % NC volume was significantly greater in DES than BMS: 19.5% vs. 12.1% (p=0.006) significantly increased with time in BMS (p=0.007), but not in DES (p=0.24) was greater in DES than in BMS at at any given time point. VH-IVUS in-stent VH-TCFAs were detected only in DES: 34.8% vs. 0% (p=0.013) Wakabayashi et al. J Inv Cardiol 2011;23:262-8

Late DES Catch-Up Among IVUS Substudy Patients %IH volume 25 Cypher FIM (SR) 20 15 10 5 0 Baseline Early* 2 years *defined as 4-9 months Cypher FIM (FR) ASPECT (low dose) ASPECT (high dose) TAXUS-II Double Dose Diabetes (single dose SES) Double Dose Diabetes (double dose SES) AMC (SES) AMC (PES)

IVUS analysis of 23 very late DES thrombosis cases at Asan Medical Center LSM was observed in 17 DES patients (73.9%) Disease progression with neointimal rupture within the stent was observed in 10 DES patients (43.5%) and reference segment plaque rupture in another 5 DES patients (21.7%) Lee et al. J Am Coll Cardiol 2010;55:1936-42

Proximal Distal 0 1.5 7.5mm

Correlation of IVUS Findings With Aspirates in 28 Patients with Very Late DES Thrombosis 28 pts with very late DES ST and 26 controls LSM in 73% of very late DES ST segments. Maximal LSM area measured 6.2±2.4mm 2, and length measured 9.4±9.5mm. LSM area exceeded 5.0mm 2 in 5 of 8 segments (63%) Controls WBCs p Eos p Spontaneous MI 291±94± 7±10± Early ST-BMS 146±117 1±1 Early ST-DES 73±117 1±2 Very late ST-BMS 84±50 2±3 0.0001 0.038 Very late ST-DES 283±149 20±24 LSM area correlated with total eosinophil count (p=0.008) Cook et al. Circulation 2009;120:391-9

Comparison Among OCT, VH-IVUS, and Grayscale IVUS Neotintimal rupture OCT + OCT - Grayscale IVUS + 3 0 Grayscale IVUS - 16 13 TCFA VH-IVUS + 9 1 VH-IVUS - 6 16 Agreement=50% Agreement=78% Thrombus Grayscale IVUS + 3 1 Grayscale IVUS - 17 11 Agreement=44% Kang et al. Circulation 2011;123:2954-2963

Conclusion There is emerging evidence -- from pathology, VH- IVUS, and especially OCT (but least with grayscale IVUS) -- of the development of in-stent neoatherosclerosis While not a universal finding, in-stent neoatherosclersis is more common in DES than in BMS and occurs earlier in DES than in BMS In-stent neoatherosclerosis is responsible for some cases of very late stent thrombosis as well as late catch-up (late in-stent restenosis).